On July 10, 2025, Avidity Biosciences (RNA, Financial) received significant attention from Goldman Sachs as analyst Corinne Johnson reinstated coverage on the biotechnology company. The analyst assigned a 'Buy' rating to the stock, marking a favorable outlook for the firm.
In addition to the reinstatement, Goldman Sachs announced a price target of $55.00 USD for Avidity Biosciences (RNA, Financial). This new target indicates optimism from the financial institution regarding the potential future performance of the stock.
Avidity Biosciences (RNA, Financial) is currently under the spotlight as investors assess the implications of this endorsement by a major financial services company. The stock, traded on the NASDAQ, is expected to see movement as the market reacts to this latest coverage and guidance from Goldman Sachs.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for Avidity Biosciences Inc (RNA, Financial) is $65.17 with a high estimate of $96.00 and a low estimate of $50.00. The average target implies an upside of 106.58% from the current price of $31.55. More detailed estimate data can be found on the Avidity Biosciences Inc (RNA) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, Avidity Biosciences Inc's (RNA, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Avidity Biosciences Inc (RNA, Financial) in one year is $11.73, suggesting a downside of 62.82% from the current price of $31.545. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Avidity Biosciences Inc (RNA) Summary page.
